A healthy 54-year-old woman was referred to our dermatology clinic with oedematous pruritic erythema and squamous papules symmetrically distributed on her trunk and extremities (Fig. 1a and b). The patient did not have mucosal lesions, but reported arthralgia and stiffness involving the toes, knees, elbows and wrists. She was referred to our clinic from rheumatology due to the symptoms persisting for 3 weeks. Despite treatment with topical corticosteroids, blisters gradually appeared over a period of several weeks with sign of Köbnerization (Fig. 1c). Laboratory findings were unremarkable, and she was seronegative for antinuclear antibodies, rheumatoid factor, anti-cyclic citrullinated peptide antibody, and anti-BP180 (NC16A)/BP230 antibodies. Hepatitis B/C virus infection was ruled out.

What is your diagnosis? See next page for answer.
Skin biopsy taken from squamous erythema comprised a typical lichenoid tissue reaction (band-like infiltration of small round cells in the upper dermis, liquefaction degeneration, and foci of wedge-shaped hypergranulosis), albeit occasional eosinophil infiltration was noted (Fig. 2a). The blistering part was composed of the subepidermal bulla, and the blister roof had occasional necrotic figures of keratinocytes (Fig. 2b). Indirect immunofluorescence revealed linear IgG deposition along the blister roof (Fig. 2c). Collectively, the final diagnosis of lichen planus pemphigoides (LPP) was given.

LPP and bullous lichen planus (BLP) are rare subepidermal blistering disorders that share clinicopathological features of lichen planus (LP). Because of the presence of circulating autoantibodies, blisters can appear in normal-looking skin in LPP, whereas BLP primarily affects pre-existing LP lesions (1–3). Therefore, immunofluorescent studies are instrumental in differentiating LPP from BLP, the latter of which shows negativity (1, 3). Both LPP and bullous pemphigoid (BP) autoantibodies recognize the extracellular domain of type-XVII collagen (BP180); however, it has been shown that LPP autoantibodies preferentially react with the carboxy-terminus, whereas BP autoantibodies recognize the amino-terminus of the BP180 non-collagenous 16A (NC16A) domain (2). Thus, we undertook a flow cytometric analysis to determine if the patient’s serum reacts with the full-length BP180 expressed in HEK293T cells (Appendix S1). The patient’s serum reacted with the BP180 protein comparably to the sera of patients with BP (Fig. 2d and Fig. S1). Titration of antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) proteins revealed positivity and negativity for anti-spike and anti-nucleocapsid IgG, respectively (5), refuting the possibility of community-acquired COVID-19 infection. As previously suggested, the clinical symptoms were manageable with administration of oral corticosteroid (6).

Including LPP, skin rashes are a well-recognized side-effect of vaccination against infectious diseases, such as influenza (7), hepatitis B (8), or human papillomavirus diseases (9). According to reports from Europe, eruptions associated with the mRNA SARS-CoV-2 vaccine vaccine are phenotypically diverse, mimicking urticaria, pityriasis rosea, or chilblains (10). Pruritic blisters accompanied by eosinophil infiltration observed in the current case resemble BP-like eruptions associated with the mRNA SARS-CoV-2 vaccine (11). Subepidermal blistering eruptions can occur after the first or second doses (6). The patient developed LPP the day after the second dose of mRNA COVID-19 vaccine (Comirnaty®, BioNTech/Pfizer (Mainz, Rhineland-Palatinate, Germany/New York, NY, USA)). This rapid onset implies transient bystander immune activation (6), presumably related to pattern recognition receptor activation in antigen-presenting cells that took up nucleic acids (12). It may also be possible that the vaccination activated pre-existing subclinical autoimmunity (6), given that the patient allegedly had itchy non-blistering erythema on her upper arm several decades before vaccination. The inherent adjuvant effect that augments recall responses (12), in addition to deduced cross-reactivity of the SARS-CoV-2 spike protein with endogenous tissue proteins (13), may underlie the cutaneous adverse reactions.

It should be noted that mRNA vaccination can incrementally evoke inflammatory responses, including fever, fatigue,
headache, arthralgia (12), or myocarditis (14). Therefore, in the current case, the second dose of mRNA vaccination appears to be primarily responsible for the strong adverse reactions, i.e. widespread blistering papulosquamous erythema with arthralgia, as indicated previously (12).

More than 50% of people are fully vaccinated against COVID-19 worldwide and awaiting the third booster shot (15). Dermatologists need to be aware of vaccination-related complications in the skin during the ongoing COVID-19 pandemic.

REFERENCES

1. Hubner F, Langan EA, Recke A. Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering. Front Immunol 2019; 10: 1389.
2. Zillikens D, Caux F, Mascaro JM, Wesselmann U, Schmidt E, Prost C, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113: 117–121.
3. Gawroñder DJ, Stavropoulos PG, McLaren KM, Buxton PK. Bullous lichen planus and lichen planus pemphigoides – clinico-pathological comparisons. Clin Exp Dermatol 1989; 14: 150–153.
4. Yamashita C, Arase N, Higuchi S, Arase H, Takagi J, Nojima S, et al. Serum autoantibodies against the extracellular region of alpha6beta4 integrin in a patient with dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. JAAD Case Rep 2022; 20: 65–68.
5. Liu Y, Soh WT, Kishikawa JJ, Hirose M, Nakayama EE, Li S, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 2021; 184: 3452–3466.e8.
6. Tomayko MM, Damsky W, Fathy R, McMahon DE, Turner N, Valentin MN, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol 2021; 148: 750–751.
7. Sato NA, Kano Y, Shiohara T. Lichen planus occurring after influenza vaccination: report of three cases and review of the literature. Dermatology 2010; 221: 296–299.
8. Rebora A, Rongaletti F, Drago F, Parodi. Lichen planus as a side effect of HBV vaccination. Dermatology 1999; 198: 1–2.
9. Laschinger ME, Schleichert RA, Green B. Lichenoid drug eruption after human papillomavirus vaccination. Pediatr Dermatol 2015; 32: e48–e49.
10. Farinazzo E, Ponis G, Zelin E, Errichetti E, Stingo G, Pinzani C, et al. Cutaneous adverse reactions after mRNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol 2021; 35: e548–e551.
11. Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 2022; 49: 34–41.
12. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615.
13. Vojvani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol 2020; 217: 108480.
14. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after covid-19 vaccination in a large health care organization. N Engl J Med 2021; 385: 2132–2139.
15. Iketani S, Liu L, Nair MS, Mohri H, Wang M, Huang Y, et al. A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth. medRxiv 2021.